Combined radiochemotherapy in localised small-cell lung cancer. Concurrent treatment protocols?
We retrospectively reviewed our Institution's database to investigate the outcome and impact of combined radiochemotherapy (RT/CT; concomitant or in sequence) in localised small-cell lung cancer (L-SCLC). Between January 1995 to November 1999, 79 patients with L-SCLC received combined RT/CT at...
Gespeichert in:
| Veröffentlicht in: | Clinical & translational oncology 2005-08, Vol.7 (7), p.314 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | spa |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | 314 |
| container_title | Clinical & translational oncology |
| container_volume | 7 |
| creator | Lucas Calduch, Ana Arnaiz Fernández, María Dolores San José Maderuelo, Sol Navarro Pérez, Valentí Serrano Bermúdez, Gala Montes Borinaga, Ana Cardenal Alemany, Felipe Jeremic, Branislav Guedea Edo, Ferran |
| description | We retrospectively reviewed our Institution's database to investigate the outcome and impact of combined radiochemotherapy (RT/CT; concomitant or in sequence) in localised small-cell lung cancer (L-SCLC).
Between January 1995 to November 1999, 79 patients with L-SCLC received combined RT/CT at our Institution. RT was delivered concurrently or sequentially following the CT. Patients with treatment response received additional prophylactic cranial irradiation (PCI).
Of the patients treated, 54% had received concurrent CT/RT compared to 46% receiving RT following the CT. PCI was administered to 80% of the patients. Complete response was observed in 66% of patients. With a median follow up of 30 months, median overall survival was 15.9 months; 14.3 months for patients who received RT following CT and 21.6 months for those receiving concurrent CT/RT. The type of schedule of combined radiochemotherapy was an independent prognostic factor for survival free of local recurrence, as was additional PCI for distant metastasis-free survival.
Our results are similar to those reported previously in the literature. The main point of interest is that our patients were non-selected. We strongly support the use of concurrent CT/RT so as to achieve results comparable to the best in the literature. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_16185594</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16185594</sourcerecordid><originalsourceid>FETCH-LOGICAL-p544-e12350ddb778c0210873b449be611d9f8ad1183e35ab9e3b644f5536ad44b5393</originalsourceid><addsrcrecordid>eNo1j8tKAzEYhbNQbK2-guQFRpImmUlWIoM3KLjpwt3wJ_nHjuQyJNNF396KujoHPjh854KseWtMw6T-WJHrWr8YU6rl_IqseMu1UkauydDnaKeEnhbwU3YHjHk5YIH5RKdEQ3YQpnrGNUIIjcMQaDimT-ogOSz3tM_JHUvBtNClICzxp80lL9nlUB9uyOUIoeLtX27I_vlp3782u_eXt_5x18xKygb5Vijmve067diWM90JK6WxePb1ZtTgOdcChQJrUNhWylEp0YKX0iphxIbc_c7ORxvRD3OZIpTT8H9UfAMy50-p</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Combined radiochemotherapy in localised small-cell lung cancer. Concurrent treatment protocols?</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Lucas Calduch, Ana ; Arnaiz Fernández, María Dolores ; San José Maderuelo, Sol ; Navarro Pérez, Valentí ; Serrano Bermúdez, Gala ; Montes Borinaga, Ana ; Cardenal Alemany, Felipe ; Jeremic, Branislav ; Guedea Edo, Ferran</creator><creatorcontrib>Lucas Calduch, Ana ; Arnaiz Fernández, María Dolores ; San José Maderuelo, Sol ; Navarro Pérez, Valentí ; Serrano Bermúdez, Gala ; Montes Borinaga, Ana ; Cardenal Alemany, Felipe ; Jeremic, Branislav ; Guedea Edo, Ferran</creatorcontrib><description>We retrospectively reviewed our Institution's database to investigate the outcome and impact of combined radiochemotherapy (RT/CT; concomitant or in sequence) in localised small-cell lung cancer (L-SCLC).
Between January 1995 to November 1999, 79 patients with L-SCLC received combined RT/CT at our Institution. RT was delivered concurrently or sequentially following the CT. Patients with treatment response received additional prophylactic cranial irradiation (PCI).
Of the patients treated, 54% had received concurrent CT/RT compared to 46% receiving RT following the CT. PCI was administered to 80% of the patients. Complete response was observed in 66% of patients. With a median follow up of 30 months, median overall survival was 15.9 months; 14.3 months for patients who received RT following CT and 21.6 months for those receiving concurrent CT/RT. The type of schedule of combined radiochemotherapy was an independent prognostic factor for survival free of local recurrence, as was additional PCI for distant metastasis-free survival.
Our results are similar to those reported previously in the literature. The main point of interest is that our patients were non-selected. We strongly support the use of concurrent CT/RT so as to achieve results comparable to the best in the literature.</description><identifier>ISSN: 1699-048X</identifier><identifier>PMID: 16185594</identifier><language>spa</language><publisher>Italy</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carcinoma, Small Cell - drug therapy ; Carcinoma, Small Cell - radiotherapy ; Carcinoma, Small Cell - therapy ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Combined Modality Therapy ; Cranial Irradiation ; Disease-Free Survival ; Esophagitis - etiology ; Etoposide - administration & dosage ; Etoposide - adverse effects ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - radiotherapy ; Lung Neoplasms - therapy ; Male ; Middle Aged ; Neutropenia - etiology ; Radiation Pneumonitis - etiology ; Radiotherapy - adverse effects ; Remission Induction ; Retrospective Studies ; Survival Analysis ; Treatment Outcome</subject><ispartof>Clinical & translational oncology, 2005-08, Vol.7 (7), p.314</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16185594$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lucas Calduch, Ana</creatorcontrib><creatorcontrib>Arnaiz Fernández, María Dolores</creatorcontrib><creatorcontrib>San José Maderuelo, Sol</creatorcontrib><creatorcontrib>Navarro Pérez, Valentí</creatorcontrib><creatorcontrib>Serrano Bermúdez, Gala</creatorcontrib><creatorcontrib>Montes Borinaga, Ana</creatorcontrib><creatorcontrib>Cardenal Alemany, Felipe</creatorcontrib><creatorcontrib>Jeremic, Branislav</creatorcontrib><creatorcontrib>Guedea Edo, Ferran</creatorcontrib><title>Combined radiochemotherapy in localised small-cell lung cancer. Concurrent treatment protocols?</title><title>Clinical & translational oncology</title><addtitle>Clin Transl Oncol</addtitle><description>We retrospectively reviewed our Institution's database to investigate the outcome and impact of combined radiochemotherapy (RT/CT; concomitant or in sequence) in localised small-cell lung cancer (L-SCLC).
Between January 1995 to November 1999, 79 patients with L-SCLC received combined RT/CT at our Institution. RT was delivered concurrently or sequentially following the CT. Patients with treatment response received additional prophylactic cranial irradiation (PCI).
Of the patients treated, 54% had received concurrent CT/RT compared to 46% receiving RT following the CT. PCI was administered to 80% of the patients. Complete response was observed in 66% of patients. With a median follow up of 30 months, median overall survival was 15.9 months; 14.3 months for patients who received RT following CT and 21.6 months for those receiving concurrent CT/RT. The type of schedule of combined radiochemotherapy was an independent prognostic factor for survival free of local recurrence, as was additional PCI for distant metastasis-free survival.
Our results are similar to those reported previously in the literature. The main point of interest is that our patients were non-selected. We strongly support the use of concurrent CT/RT so as to achieve results comparable to the best in the literature.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carcinoma, Small Cell - drug therapy</subject><subject>Carcinoma, Small Cell - radiotherapy</subject><subject>Carcinoma, Small Cell - therapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Combined Modality Therapy</subject><subject>Cranial Irradiation</subject><subject>Disease-Free Survival</subject><subject>Esophagitis - etiology</subject><subject>Etoposide - administration & dosage</subject><subject>Etoposide - adverse effects</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - radiotherapy</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neutropenia - etiology</subject><subject>Radiation Pneumonitis - etiology</subject><subject>Radiotherapy - adverse effects</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>1699-048X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j8tKAzEYhbNQbK2-guQFRpImmUlWIoM3KLjpwt3wJ_nHjuQyJNNF396KujoHPjh854KseWtMw6T-WJHrWr8YU6rl_IqseMu1UkauydDnaKeEnhbwU3YHjHk5YIH5RKdEQ3YQpnrGNUIIjcMQaDimT-ogOSz3tM_JHUvBtNClICzxp80lL9nlUB9uyOUIoeLtX27I_vlp3782u_eXt_5x18xKygb5Vijmve067diWM90JK6WxePb1ZtTgOdcChQJrUNhWylEp0YKX0iphxIbc_c7ORxvRD3OZIpTT8H9UfAMy50-p</recordid><startdate>200508</startdate><enddate>200508</enddate><creator>Lucas Calduch, Ana</creator><creator>Arnaiz Fernández, María Dolores</creator><creator>San José Maderuelo, Sol</creator><creator>Navarro Pérez, Valentí</creator><creator>Serrano Bermúdez, Gala</creator><creator>Montes Borinaga, Ana</creator><creator>Cardenal Alemany, Felipe</creator><creator>Jeremic, Branislav</creator><creator>Guedea Edo, Ferran</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200508</creationdate><title>Combined radiochemotherapy in localised small-cell lung cancer. Concurrent treatment protocols?</title><author>Lucas Calduch, Ana ; Arnaiz Fernández, María Dolores ; San José Maderuelo, Sol ; Navarro Pérez, Valentí ; Serrano Bermúdez, Gala ; Montes Borinaga, Ana ; Cardenal Alemany, Felipe ; Jeremic, Branislav ; Guedea Edo, Ferran</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p544-e12350ddb778c0210873b449be611d9f8ad1183e35ab9e3b644f5536ad44b5393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>spa</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carcinoma, Small Cell - drug therapy</topic><topic>Carcinoma, Small Cell - radiotherapy</topic><topic>Carcinoma, Small Cell - therapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Combined Modality Therapy</topic><topic>Cranial Irradiation</topic><topic>Disease-Free Survival</topic><topic>Esophagitis - etiology</topic><topic>Etoposide - administration & dosage</topic><topic>Etoposide - adverse effects</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - radiotherapy</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neutropenia - etiology</topic><topic>Radiation Pneumonitis - etiology</topic><topic>Radiotherapy - adverse effects</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lucas Calduch, Ana</creatorcontrib><creatorcontrib>Arnaiz Fernández, María Dolores</creatorcontrib><creatorcontrib>San José Maderuelo, Sol</creatorcontrib><creatorcontrib>Navarro Pérez, Valentí</creatorcontrib><creatorcontrib>Serrano Bermúdez, Gala</creatorcontrib><creatorcontrib>Montes Borinaga, Ana</creatorcontrib><creatorcontrib>Cardenal Alemany, Felipe</creatorcontrib><creatorcontrib>Jeremic, Branislav</creatorcontrib><creatorcontrib>Guedea Edo, Ferran</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Clinical & translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lucas Calduch, Ana</au><au>Arnaiz Fernández, María Dolores</au><au>San José Maderuelo, Sol</au><au>Navarro Pérez, Valentí</au><au>Serrano Bermúdez, Gala</au><au>Montes Borinaga, Ana</au><au>Cardenal Alemany, Felipe</au><au>Jeremic, Branislav</au><au>Guedea Edo, Ferran</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combined radiochemotherapy in localised small-cell lung cancer. Concurrent treatment protocols?</atitle><jtitle>Clinical & translational oncology</jtitle><addtitle>Clin Transl Oncol</addtitle><date>2005-08</date><risdate>2005</risdate><volume>7</volume><issue>7</issue><spage>314</spage><pages>314-</pages><issn>1699-048X</issn><abstract>We retrospectively reviewed our Institution's database to investigate the outcome and impact of combined radiochemotherapy (RT/CT; concomitant or in sequence) in localised small-cell lung cancer (L-SCLC).
Between January 1995 to November 1999, 79 patients with L-SCLC received combined RT/CT at our Institution. RT was delivered concurrently or sequentially following the CT. Patients with treatment response received additional prophylactic cranial irradiation (PCI).
Of the patients treated, 54% had received concurrent CT/RT compared to 46% receiving RT following the CT. PCI was administered to 80% of the patients. Complete response was observed in 66% of patients. With a median follow up of 30 months, median overall survival was 15.9 months; 14.3 months for patients who received RT following CT and 21.6 months for those receiving concurrent CT/RT. The type of schedule of combined radiochemotherapy was an independent prognostic factor for survival free of local recurrence, as was additional PCI for distant metastasis-free survival.
Our results are similar to those reported previously in the literature. The main point of interest is that our patients were non-selected. We strongly support the use of concurrent CT/RT so as to achieve results comparable to the best in the literature.</abstract><cop>Italy</cop><pmid>16185594</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1699-048X |
| ispartof | Clinical & translational oncology, 2005-08, Vol.7 (7), p.314 |
| issn | 1699-048X |
| language | spa |
| recordid | cdi_pubmed_primary_16185594 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Small Cell - drug therapy Carcinoma, Small Cell - radiotherapy Carcinoma, Small Cell - therapy Cisplatin - administration & dosage Cisplatin - adverse effects Combined Modality Therapy Cranial Irradiation Disease-Free Survival Esophagitis - etiology Etoposide - administration & dosage Etoposide - adverse effects Humans Lung Neoplasms - drug therapy Lung Neoplasms - radiotherapy Lung Neoplasms - therapy Male Middle Aged Neutropenia - etiology Radiation Pneumonitis - etiology Radiotherapy - adverse effects Remission Induction Retrospective Studies Survival Analysis Treatment Outcome |
| title | Combined radiochemotherapy in localised small-cell lung cancer. Concurrent treatment protocols? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T16%3A08%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combined%20radiochemotherapy%20in%20localised%20small-cell%20lung%20cancer.%20Concurrent%20treatment%20protocols?&rft.jtitle=Clinical%20&%20translational%20oncology&rft.au=Lucas%20Calduch,%20Ana&rft.date=2005-08&rft.volume=7&rft.issue=7&rft.spage=314&rft.pages=314-&rft.issn=1699-048X&rft_id=info:doi/&rft_dat=%3Cpubmed%3E16185594%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16185594&rfr_iscdi=true |